MEI Pharma Adopts Litecoin Treasury, Adds Litecoin Creator Charlie Lee to Board
MEI Pharma announced today it will establish a dedicated Litecoin treasury as part of a broader strategy to integrate cryptocurrency into its corporate structure. The initiative, led by Titan Partners Group in partnership with crypto investment firm GSR, has secured commitments exceeding $100 million. As part of the move, Charlie Lee, creator of Litecoin, will join MEI Pharma’s Board of Directors. The Litecoin Foundation has also made a strategic investment in the company, citing alignment with its mission to promote global adoption of Litecoin as a mainstream digital payment option. Strategic Shift Toward Cryptocurrency The decision marks a significant shift for MEI Pharma, traditionally focused on clinical-stage oncology, into digital assets and blockchain infrastructure. According to company representatives, the new Litecoin treasury is intended to diversify MEI Pharma’s balance sheet while exploring cryptocurrency as a potential hedge and operational tool. Charlie Lee emphasized Litecoin’s long-standing stability and utility as a low-cost payments network. “For 14 years, Litecoin has consistently delivered a stable, low-cost, and accessible network for millions and over a decade,” Lee said in a statement. This partnership with GSR and MEI Pharma brings that utility and mission into an institutional setting for the first time. GSR, which has experience structuring digital asset treasuries, will support the treasury’s integration and management, though detailed plans for the fund’s use and oversight remain to be finalized. Litecoin Foundation Invests in Corporate Strategy The Litecoin Foundation’s investment in MEI Pharma underscores its commitment to institutional partnerships that could expand real-world use of the cryptocurrency. The foundation described the move as part of its broader effort to drive adoption beyond retail and remittance markets into corporate finance. Since founding Litecoin in 2011, Lee has become a recognized figure in cryptocurrency circles. His work has included advocacy for technical upgrades such as Segregated Witness (SegWit) and development support for initiatives like the Lightning Network. These efforts have contributed to Litecoin’s integration on major payment processors, including BitPay. Despite the pivot into digital assets, MEI Pharma has not announced changes to its ongoing pharmaceutical research and development programs. The company did not specify whether the Litecoin treasury would directly fund clinical operations or remain a separate financial asset. The strategic partnership with GSR and the addition of Lee to the board mark MEI Pharma’s first significant step into blockchain technology. Further details about governance, treasury strategy, and potential applications are expected in future announcements.